

SATURDAY EVALUATION FORM

September 21, 2024 • Thyroid Cancer Survivors' 27th International Conference

8:00 a.m. - 8:50 a.m.	
201 De-escalation strategies for low-risk thyroid cancer including decreasing extent of surgery or non-surgical options such as ablation. Victoria E. Banuchi, MD, MPH, Otolaryngologist.	1 2 3 4 5
202 Your questions about papillary, follicular and oncocytic (formerly Hurthle Cell) thyroid cancers and variants answered by a doctor. Valentina D. Tarasova, MD, Endocrinologist	1 2 3 4 5
203 Medullary thyroid cancer roundtable: Welcoming people who weren't able to join us yesterday, and clarifying any confusion from day 1. Bill Nelson and Kelley Pratt, ThyCa Volunteers.	1 2 3 4 5
204 Use of thyroglobulin in patient management after thyroid surgery. Trevor E. Angell, MD, Endocrinologist	1 2 3 4 5
9:15 a.m. - 10:15 a.m.	
226 Keynote - Managing PTSD and anxiety following a cancer diagnosis: Effective strategies to navigate. Studies show more than 35 percent of cancer survivors experience feelings of Post-Traumatic Stress (PTS). PTS is similar to post-traumatic stress disorder (PTSD) experienced by military veterans and survivors of natural disasters or life-threatening events. When someone in a family is diagnosed with cancer, it affects everyone. This creates a continuous cycle of fear and anxiety, which can lead to Post-Traumatic Stress or a diagnosis of PTSD. In this one-hour presentation, psychologist Dr. Ann Friedman and trauma-survivor Shawn Alex Nemeth shine a light on this complex issue and equip participants with evidenced-based tools to relieve fear and anxiety. Ann Friedman, PhD, Psychologist, and	1 2 3 4 5
10:45 a.m. - 11:45 a.m.	
231 A preview of the next iteration of the American Thyroid Association guidelines for differentiated thyroid cancer (papillary, follicular, and oncocytic thyroid cancer). Julie Ann Sosa, MD, MA, Surgeon	1 2 3 4 5
232 Papillary thyroid cancer, a panel discussion - symptoms to surveillance. Part 1. Christina Bui, MSN, APRN, FNP-C, Nurse Practitioner, Savannah Cheatham, MPAS, PA-C, Physician Assistant, Julia Diersing, MS, PA-C, Physician Assistant, Barbara Ebersole, MA, CCC-SLP, Speech-Language Pathologist, Soo-Hyun Lee-Kim, MS, APRN, FNP-C, Nurse Practitioner, Rachna Patel, MPH, BSN, MSN, FNP-BC, Nurse Practitioner, and Johnny L. Rollins, MSN, APRN, ANP-C, Advanced Practice Provider.	1 2 3 4 5
233 Medullary thyroid cancer: Considerations before, during, and after surgery. Mark E. Zafereo, MD, Head and Neck Surgeon	1 2 3 4 5
234 Anti-obesity drugs and thyroid cancer. Sonya Khan, MD, Endocrinologist.	1 2 3 4 5
234 Roundtable: Questions you may have about oral care after cancer treatment. Richard C. Cardoso, D.D.S., M.S., Oral Medicine Specialist	1 2 3 4 5
235 The ABCs of papillary and follicular thyroid cancer and variants: Understanding key terms, concepts, and initial diagnostic and treatment steps. Priyanka C. Iyer, MD, Oncologic Endocrinologist	1 2 3 4 5
12:15 p.m. - 1:15 p.m.	
241 Advanced Thyroid Cancer. Priyanka C. Iyer, MD, Oncologic Endocrinologist.	1 2 3 4 5
242 Papillary thyroid cancer, a panel discussion - symptoms to surveillance. Part 2. Christina Bui, MSN, APRN, FNP-C, Nurse Practitioner, Savannah Cheatham, MPAS, PA-C, Physician Assistant, Julia Diersing, MS, PA-C, Physician Assistant, Barbara Ebersole, MA, CCC-SLP, Speech-Language Pathologist, Soo-Hyun Lee-Kim, MS, APRN, FNP-C, Nurse Practitioner, Rachna Patel, MPH, BSN, MSN, FNP-BC, Nurse Practitioner, and Johnny L. Rollins, MSN, APRN, ANP-C, Advanced Practice	1 2 3 4 5
243 Update in medullary thyroid cancer clinical trials. Mark E. Zafereo, MD, Head and Neck Surgeon.	1 2 3 4 5
244 The use of Thyrogen® versus T4 withdrawal to prepare for radioactive iodine treatment or scans and/or for stimulated thyroglobulin testing, with or without scans.	1 2 3 4 5
245 Am I a candidate for a non-surgical treatment option? A discussion about percutaneous alcohol ablation, and thermal ablation procedures. Moderator: Jennifer Holkem, SYT Founder. Panelists: Jules Aljammal, MD, ECNU, Endocrinologist, Juan C. Camacho, MD, Vascular and Interventional Radiologist, and Jonathon O. Russell, MD, Thyroid Surgeon.	1 2 3 4 5
1:45 p.m. - 2:45 p.m.	
251 The team approach to thyroid cancer management. Michelle S. Mullin, RN, Nurse Navigator, Brenna Newfell, NP, Nurse Practitioner, and Theodora Pappa, MD, PhD, Onco-Endocrinologist.	1 2 3 4 5
252 Systemic therapies in advanced radioactive iodine refractory (non-avid, RAI-R) differentiated thyroid cancer. Whitney S. Goldner, MD, Endocrinologist.	1 2 3 4 5
253 Roundtable: Discussion about rare fusions (ALK, nTRK, PTC-RET) in thyroid cancer. Julie Martwick, and Susan Spinosa, ThyCa Volunteers, and Lori J. Wirth, MD, Medical Oncologist	1 2 3 4 5
254 Discussion about the low-iodine diet. Daria Jerauld and Becky Johnson ThyCa Volunteers.	1 2 3 4 5
255 Roundtable: Empowering adolescent and young adult (AYA) thyroid cancer survivors in your medical appointments. For people ages 18 to 35. Amanda L. Silver Karcioğlu, MD, Otolaryngologist.	1 2 3 4 5
256 Haga sus preguntas a el médico en español Maria E. Cabanillas, MD, Endocrinólogo Oncológico	1 2 3 4 5
3:15 p.m. - 4:15 p.m.	
261 Extent of surgery for primary thyroid cancer and recurrent thyroid cancer. Allen S. Ho, MD, Surgeon	1 2 3 4 5
262 Pre-operative evaluation of thyroid cancer including the importance of having an accurate ultrasound before surgery and cross-sectional imaging in patients with aggressive thyroid cancer or bulky lymphadenopathy. Sara Ahmadi, MD,	1 2 3 4 5
263 CAR T-cell therapy for medullary thyroid cancer: The personal story and the science. Roger B. Cohen, MD, Medical Oncologist	1 2 3 4 5
264 Update on treatment of anaplastic thyroid cancer. Maria E. Cabanillas, MD, Oncologic Endocrinologist.	1 2 3 4 5

265 Roundtable: Tips and tricks for managing anxiety and distress for adolescent and young adult (AYA) thyroid cancer survivors. For people ages 18 to 35. Sara Lampert-Okin	1 2 3 4 5
266 How we approach thyroid cancer management in pediatric thyroid cancer. Luz E. Castellanos, MD, Pediatric Endocrinologist	1 2 3 4 5
4:45 p.m. -5:45 p.m.	
271 Repet neck surgeries: What to expect. Allen S. Ho, MD, Surgeon.	1 2 3 4 5
272 Immunotherapy and immunotherapy combinations with targeted therapy in follicular cell-derived thyroid cancers. Jochen J. Lorch, MD, MSc, Medical Oncologist	1 2 3 4 5
273 Neoadjuvant therapy followed by surgery in all types of thyroid cancer. Anastasios Maniakas, MD, PhD, FRCSC, Otolaryngologist	1 2 3 4 5
274 Modeling center of excellence practices to improve the care of patients with biomarker driven thyroid cancer or non-small-cell lung cancer. “Provided by The University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL) and supported by an educational grant from Lilly. This activity is approved for AMA PRA Category 1 Credit.” Lori J. Wirth, MD, Medical Oncologist	1 2 3 4 5
275 Considerations in treatment of advanced pediatric thyroid cancer, including clinical trials. Steven G. Waguespack, MD, Endocrinologist	1 2 3 4 5

1. Which sessions did you find most helpful today?

2. Comments and suggestions: